	US 12,239,644 B2
	Composition for prevention or treatment of macular degeneration
Dong Ho Park, Daegu (KR); and In Kyu Lee, Daegu (KR)
Assigned to KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
Appl. No. 17/282,547
Filed by KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
PCT Filed Oct. 30, 2019, PCT No. PCT/KR2019/014500 § 371(c)(1), (2) Date Apr. 2, 2021, PCT Pub. No. WO2020/091430, PCT Pub. Date May 7, 2020.
Claims priority of application No. 10-2018-0133677 (KR), filed on Nov. 2, 2018; and application No. 10-2019-0136771 (KR), filed on Oct. 30, 2019.
Prior Publication US 2021/0369708 A1, Dec. 2, 2021
Int. Cl. A61K 31/506 (2006.01); A61P 27/02 (2006.01)

CPC A61K 31/506 (2013.01) [A61P 27/02 (2018.01)]

5 Claims

1. A method for alleviating, preventing, or treating of macular degeneration in a subject, the method consisting of:

administering to the subject a pharmaceutical composition, wherein the pharmaceutical composition consists of fursultiamine or a salt thereof as the sole active ingredient for alleviating, preventing, or treating macular degeneration, and a pharmaceutically acceptable carrier or excipient.